| Laryngeal preservation by treatment with induction chemotherapy and radiotherapy protocol for stage III & IV carcinoma larynx--results of a pilot study. | |
| | |
MedLine Citation:
|
PMID: 10505156 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Total laryngectomy for advanced carcinoma of the larynx is effective but functionally disabling. In an effort at laryngeal preservation, 33 patients of stage III/IV carcinoma larynx were treated between 1987 and 1991 with induction chemotherapy followed by definitive radiation. Two chemotherapy protocols were administered. Group I patients received one to three cycles of cisplatin 100 mg/m2 (day 1), bleomycin 15 U/m2 (day 1), and 5-fluorouracil 1000 mg/m2/day (day 2 to 5) at three weekly intervals. This was then followed by radiotherapy. Group II received one to six weekly injections of single agent methotrexate 50 mg/m2 with or without leucocovorin rescue followed by radiotherapy. Any recurrence was salvaged by surgery. Midway through the study, Group II protocol was discontinued as the initial results were not comparable with Group I or standard treatment. The Group I protocol, however, yielded an initial locoregional control rate of 83.3 per cent With the addition of surgical salvage the locoregional control rate was 94.4 per cent and the control rate with laryngeal preservation was 88.8 per cent. The Kaplan-Meier probability of two years and five years disease-free survival was 81.9 per cent and 61.4 per cent respectively. For disease-free survival with laryngeal preservation the corresponding figures for two years and five years were 58.3 per cent and 41.7 per cent. The control group of 51 patients treated with radical surgery followed by radiotherapy yielded survival figures at two years and five years of 64.3 per cent and 57.2 per cent. The difference in the survival of Group I and the control group was not statistically significant (p value = 0.280). These initial results indicate that for stage III and for surgically resectable stage IV laryngeal carcinomas, a protocol of induction combination chemotherapy consisting of cisplatin, bleomycin and 5-fluorouracil followed by radiotherapy and combined with surgical salvage whenever required, can lead to comparable cure rates. In addition, a large proportion of patients are spared the morbidity of a total laryngectomy. |
| | |
Authors:
|
A Thakar; S Bahadur; D A Tandon; A Ranganathan; G K Rath |
Related Documents
:
|
3064866 - Endoluminal ultrasound and computed tomography in the staging of rectal cancer. 8689166 - Mesorectal excision for rectal cancer. 7362936 - Carcinoma of the tongue: factors affecting the results of surgical treatment. 14582656 - Total ear canal ablation in the cat: indications, morbidity and long-term survival. 23107976 - The effect of intraarterial high-dose cisplatin on lymph nodes in oral and oropharyngea... 23173846 - Local recurrence of gastric cancer after total gastrectomy: an unusual presentation. |
Publication Detail:
|
Type: Clinical Trial; Controlled Clinical Trial; Journal Article |
Journal Detail:
|
Title: The Journal of laryngology and otology Volume: 113 ISSN: 0022-2151 ISO Abbreviation: J Laryngol Otol Publication Date: 1999 May |
Date Detail:
|
Created Date: 1999-10-21 Completed Date: 1999-10-21 Revised Date: 2006-04-24 |
Medline Journal Info:
|
Nlm Unique ID: 8706896 Medline TA: J Laryngol Otol Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 433-8 Citation Subset: AIM; IM |
Affiliation:
|
Department of Otolaryngology-Head and Neck Surgery, All India Institute of Medical Sciences, New Delhi, India. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antimetabolites, Antineoplastic / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Bleomycin / administration & dosage Chemotherapy, Adjuvant Cisplatin / administration & dosage Fluorouracil / administration & dosage Humans Laryngeal Neoplasms / drug therapy*, radiotherapy, surgery Laryngectomy Male Methotrexate / therapeutic use Middle Aged Neoplasm Staging Pilot Projects Survival Rate |
| Chemical | |
Reg. No./Substance:
|
0/Antimetabolites, Antineoplastic; 0/CFB protocol; 11056-06-7/Bleomycin; 15663-27-1/Cisplatin; 51-21-8/Fluorouracil; 59-05-2/Methotrexate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Topical inhalant steroid (budesonide, Pulmicort nasal) therapy in intubation granuloma.
Next Document: Vocal fold paralysis following carotid endarterectomy.